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Abstract 
Huntington’s disease (HD) is a fully penetrant neurodegenerative disease caused by a dominantly inherited 
CAG trinucleotide repeat expansion in the huntingtin gene on chromosome 4. In Western populations HD 
has a prevalence of 10.6-13.7 individuals per 100,000. It is characterised by cognitive, motor and psychiatric 
disturbance. At the cellular level mutant huntingtin results in neuronal dysfunction and death through a 
number of mechanisms, including disruption of proteostasis, transcription and mitochondrial function and 
direct toxicity of the mutant protein. Early macroscopic changes are seen in the striatum with involvement of 
the cortex as the disease progresses. There are currently no disease modifying treatments therefore 
supportive and symptomatic management is the mainstay of treatment. In recent years there have been 
significant advances in understanding both the cellular pathology and the macroscopic structural brain 
changes that occur as the disease progresses.  In the last decade there has been a large growth in potential 
therapeutic targets and clinical trials. Perhaps the most promising of these are the emerging therapies aimed 
at lowering levels of mutant huntingtin. Antisense oligonucleotide therapy is one such approach with clinical 
trials currently underway. This may bring us one step closer to treating and potentially preventing this 
devastating condition.  
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Introduction  
In 1872 George Huntington wrote an account of hereditary chorea, which we now know as Huntington’s 
disease. He described its hereditary nature, associated psychiatric and cognitive symptoms and the 
manifestation of the disease in adult life between 30 and 40 years of age. He outlined the progressive nature 
of the disease stating, “Once it begins it clings to the bitter end” [1]. However the monogenic nature and full 
penetrance of HD makes it perhaps one of the most treatable neurodegenerative diseases. This has become 
particularly apparent in the last decade with the advent of new therapeutic approaches that can directly target 
the HD gene and prevent production of the toxic mutant huntingtin protein [2].  
Aetiology 
HD is caused by an autosomal dominantly inherited CAG trinucleotide repeat expansion in the huntingtin 
(HTT) Gene on chromosome 4. This results in the production of a mutant huntingtin (mHTT) protein with 
an abnormally long polyglutamine repeat [3]. Those with greater than 39 CAG repeats are certain to develop 
the disease, while reduced penetrance is seen between 36 to 39 repeats. Anticipation can be seen when the 
gene is passed down the paternal line, such that a father with a CAG repeat length in the intermediate range 
may have a child with an expanded pathogenic repeat length. This is because sperm from males shows 
greater repeat variability and larger repeat sizes than somatic tissues [4].  
Epidemiology 
HD has a prevalence of 10.6-13.7 individuals per 100,000 in Western populations. Japan, Taiwan and Hong 
Kong have a much lower incidence of HD with a prevalence of 1-7 per million, in South Africa lower rates 
are seen in black populations when compared to white and mixed populations. The difference in disease 
prevalence across ethnic groups relate to genetic differences in the HTT gene. Populations with a high 
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prevalence have longer average CAG repeats. For example those of European ancestry have an average if 
18.4-18.7, while those of Asian ancestry have an average of 16.9-17.4 [5].   
Pathogenesis 
Molecular pathogenesis 
mHTT results in neuronal dysfunction and death through a number of mechanisms. These include direct 
effects from the exon 1 mHTT fragment, the propensity of mHTT to form abnormal aggregates and its 
effects on cellular proteostasis, axonal transport, transcription, translation, mitochondrial and synaptic 
function [6, 7] (see figure 1). Medium spiny neurons (MSNs) of the striatum are selectively vulnerable to the 
effects of mHTT. Striatal pathology follows a biphasic course with initial loss of MSNs of the indirect 
pathway leading to a hyperkinetic phenotype followed by loss of MSNs of the direct pathway resulting in a 
hypokinetic phenotype [8]. The cause for the selective vulnerability of indirect pathway MSNs is unclear, 
however dopamine D2 receptors may be a factor as they are expressed by indirect but not direct MSNs and 
have been implicated in HD pathogenesis [9], other hypotheses include the loss of brain derived 
neurotrophic factor, glutamate excitotoxicity from cortico-striatal projections and toxic effects of repeat 
associated non-ATG (RAN) translation proteins [6][10].  
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Figure 1.  Pathogenetic cellular mechanisms in Huntington disease. (1) HTT is translated to produce the 
full-length huntingtin protein as well as an amino-terminal HTT exon1 fragment (the result of aberrant 
splicing). The length of the polyglutamine (polyQ) tract in these proteins depends on the extent of somatic 
instability. (2) Full-length native huntingtin is cleaved through proteolysis to generate additional protein 
fragments. (3) Protein fragments enter the nucleus. (4) Fragments are retained in the nucleus through self-
association, oligomerization and aggregation — leading to the formation of inclusions, a process that causes 
transcriptional dysregulation through the sequestration of other proteins and through other incompletely 
defined mechanisms. (5) Huntingtin fragments oligomerize and aggregate in the cytoplasm. (6) The 
aggregation of huntingtin is exacerbated through the disease-related impairment of the proteostasis network, 
which also leads to global cellular impairments. (7) The aberrant forms of huntingtin result in additional 
global cellular impairments, including synaptic dysfunction, mitochondrial toxicity and a decreased rate of 
axonal transport. PRD, proline-rich domain; Ub, ubiquitin. Reproduced with permissions from [7]. 
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Macroscopic pathology 
Post-mortem studies reveal diffuse atrophy of the caudate and putamen with degeneration occurring along a 
caudo-rostral, dorso-ventral and medio-lateral gradient. The globus pallidus and nucleus accumbens are also 
affected but to a lesser extent [11]. A classification system for HD pathology has been developed which 
consists of 5 grades. Grade 0: clinical evidence for HD but no gross or microscopic abnormalities that could 
be related to HD. Grade 1: No macroscopic abnormalities in the caudate or putamen but moderate fibrillary 
astrocytosis at the microscopic level. Grade 2: Macroscopic changes in the caudate and putamen but no 
macroscopic changes in the Globus Pallidus. Grade 3: lateral segment of the globus pallidus showing 
fibrillary astrocytosis with the medial segment of the GP unchanged. Grade 4: Shrunken caudate yellow-
brown in colour, widened anterior horn of lateral ventricle and smaller nucleus accumbens [12].   
 At grades 3 and 4 changes are also seen in other brain regions including the thalamus, sub-thalamic 
nucleus, white matter and cerebellum. With respect to the cerebral cortex atrophy is variable even in stages 3 
and 4 [12]. More recently advances in magnetic resonance imaging (MRI) has confirmed these early 
pathological findings in vivo, particularly loss caudate and putamen grey matter volume and loss of both 
striatal and cortical white matter [13]. 
Clinical features 
Diagnosis 
Diagnosis of HD is based on a confirmed family history or positive genetic test and the onset of motor 
disturbance as defined by the Unified HD rating scale (UHDRS) total motor score (TMS) diagnostic 
confidence score. This score ranges from 0 (no motor abnormalities suggestive of HD to 4 (≥99% to be due 
to HD), with a score of 4 defining motor onset or ‘manifest’ HD. However subtle motor, cognitive and 
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psychiatric deficits can be identified up to 10-15 before the onset of manifest disease and this is referred to 
as the premanifest stage of the disease [14]. 
CAG length and clinical phenotype  
The full penetrance of HD in mutation carriers with > 39 CAG repeats makes it an ideal model for studying 
the preclinical phase of neurodegeneration, as it is possible to predict who will develop the disease many 
years before symptom onset. Reduced penetrance is seen between 36-39 repeats [15], while 27-35 is 
considered the intermediate range and below 27 is normal.  CAG repeat length accounts for approx. 56% of 
the variability in age of onset [16] and is also correlated with progression of motor and cognitive deficits 
[17]. 
Genetic modifiers 
Genetic factors independent of CAG repeat length have also been shown to modify HD. The largest genome 
wide association study (GWAS) study in HD identified a number of genes involved in DNA repair that can 
alter the age of motor onset. Two genes on chromosome 15, FAN1 (Fanconi anemia FANC1/FANCD2-
associated endonuclease) and MTMR10 (myotubularin related protein 10) were shown to be the most 
significant. On chromosome 8 significant associations were also seen with RRM2B (a subunit of DNA 
damage p53-inducible ribonucleotide reductase M2 B) and URB5 (an HECT domain E3 ubiquitin-protein 
ligase). Genetic pathway analysis also implicated gene pathways involved in DNA repair, mitochondrial 
fission and oxidoreductase activity [18]. Similarly a recent GWAS has revealed association between HD 
progression and a genetic variant in MSH3, a DNA repair gene, associated with CAG somatic instability 
[19].  
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Natural history studies 
In recent years a number of multi-centre natural history studies have been pivotal in both our understanding 
of disease onset, progression and in the search for clinical and imaging biomarkers. The largest study to date 
is Registry, which is a European study spanning 16 countries with over 17,000 participants collecting motor, 
cognitive, behavioural and biosample data [20]. Co-operative HD Observation Research Trial (COHORT) 
[21] and Prospective Huntington At Risk Observational Study (PHAROS) [22] are both prospective 
longitudinal studies tracking changes in motor, cognitive and behavioural variables.  
In addition to extensive clinical data PREDICT and Track-HD collected imaging data across 
multiple time points. PREDICT included over 1,000 participants followed up over 10 years and focused on 
identifying measures that predict conversion to manifest HD [23]. Track-HD was a study focused on the 
evaluation of biomarkers for clinical trials and included 123 controls, 120 premanifest and 123 with 
manifest disease, followed up over 3 years [24]. This has now extended to TrackOn-HD, which aims to 
identify functional markers of pre-manifest HD and study mechanisms of brain compensation over 3 time 
points one year apart [25]. 
Motor disturbance 
In keeping with the biphasic course of striatal pathology with initial loss of MSNs of the indirect pathway 
followed by loss of MSNs of the direct pathway [8], movement disturbance in HD can be split into a 
hyperkinetic phase with prominent chorea in the early stages of the disease, which then tends to plateau [26]. 
The hypokinetic phase is chracterised by bradykinesia, dystonia, balance and gait disturbance. The 
hypokinetic movement disorder shows association with disease duration and CAG length while chorea does 
not [27].  
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Assessment of motor disturbance is based on the UHDRS TMS, which assesses eye movements, 
speech, alternating hand movements, dystonia, chorea and gait. While the UHDRS TMS is sensitive to 
change over time [28] it is also subject to inter-rater variability [29]. More quantitative assessments such as 
the (quantitative) Q-motor battery, which includes tongue force variability, grip force, speeded and self 
paced tapping [30], have shown sensitivity to longitudinal change [28]. 
Cognitive disturbance  
Cognitive disturbance can be seen many years before symptom onset and follows a sub-cortical pattern 
characterized by impaired emotion recognition, processing speed, visuospatial and executive function [31]. 
In early manifest disease longitudinal changes can be demonstrated over 12 and 24 months by performance 
on the symbol digit modalities test, which assesses psychomotor speed, Stroop word reading which assesses 
executive function and indirect circle tracing, which is used to assess visuospatial performance and the 
emotion recognition test [13, 32]. This extends to premanifest HD at 36-months, with Stroop word reading 
demonstrating the highest sensitivity for those furthest from disease onset [28].   
Neuropsychiatric disturbance 
A wide variety of neuropsychiatric symptoms occur in HD, including apathy, anxiety, irritability, depression, 
obsessive compulsive behaviour and psychosis. While high rates are seen in manifest disease [33], 
psychiatric disturbance is also common many years before symptom onset in the premanifest stage [24]. The 
most recent study from the Registry cohort, which includes both premanifest and manifest participants, 
shows that Apathy is the most common occurring in 28%, while depression, irritability and obsessive 
compulsive behavior occur in around 13%. Psychosis is relatively rare occurring in 1% [34].  
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While apathy, irritability and depression are all related to functional decline, apathy is the only 
neuropsychiatric symptom that has been shown consistently to progress with disease [28]. This may be due 
to the lack of effective treatments for apathy in comparison to the use of anti-depressants and anti-psychotics 
for depression, anxiety and irritability.  
Quality of life 
HD has a profound effect on quality of life, which begins with the diagnosis of a parent. In one study over 
50% of at risk adults reported adverse childhood events related to a diagnosis HD in the family [35].  
Reduced total functional capacity is seen after the onset of symptoms with the loss of employment and the 
need for job modification in the early stages. As the disease progresses to the end stage there is a need for 
24-hour care. Motor and cognitive decline are predictive for long-term placement in care [7].  
Figure 2. The impact of various life events and disease milestones on different domains of quality of 
life in a hypothetical person with Huntington disease. The impact of the disease on an individual’s 
quality of life begins long before the person has any symptoms of the disease. Quality-of-life domains are 
differentially affected by these events and milestones. Reproduced with permissions from [7].  
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Differential diagnoses 
In the absence of a mHTT mutation the triad of chorea, cognitive and neuropsychiatric disturbance is known 
as a HD phenocopy. While diagnosis can only be achieved in around 3% [36] of these cases there are a 
number of genetic conditions that may present as HD phenocopies. The most common of these in European 
populations are C9orf72 [37] and Spinocerebellar ataxia (SCA) 17 [36]. Additional features such as ataxia 
or peripheral neuropathy may suggest other diagnoses such as SCA 1-3 or Friedrich’s ataxia. In the case of 
seizures Dentatorubral-pallidoluysian atrophy (DRPLA) should be considered. Iron accumulation disorders 
such as Neuroferritinopathy and Neurodegeneration with brain iron acculumation (NBIA) may reveal 
abnormal MRI imaging. In the case of Neuroacanthocytosis abnormal acanthocytes can be seen on 
peripheral blood films. Huntington’s disease like syndrome 2 (HDL2) is the most common cause of HD 
phenocopies in African populations [37, 38].   
 Isolated chorea can be caused by acquired conditions including striatal pathology, chorea of 
pregnancy, systemic lupus erythematosus/anti-phospholipid syndrome, thyrotoxicosis, post infectious 
syndromes, polycythaemia rubra vera and drugs [38].  
Investigations 
Genetic testing 
Genetic testing for the mHTT mutation can either be diagnostic or predictive. In the case of a diagnostic test 
this may be performed when a patient presents with typical motor features of HD. Prior to testing it is 
important to inform the patient about HD and its hereditary nature as a positive test has implications both for 
the patient and their family. Delivering the news of a positive genetic test should be done face-to-face with 
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the patient and his/her family. The option of referral to a specialist HD management clinic should also be 
provided [39].  
 Predictive testing (PT) is done prior to symptom onset in adults who are at risk of inheriting the HTT 
gene mutation. International guidelines were established shortly after the identification of the HTT gene in 
1993 [3] and have been updated in 2013 [40]. The protocol for predictive testing consists of pretest 
counseling where the candidate is provided with information in order to make an informed decision 
regarding the risks and benefits of testing. After a period of time this is followed by a neurological 
examination to ensure the candidate is not symptomatic and then psychological screening to identify those at 
high risk of suicide in the event of a positive result. Post-test follow-up is also carried out to monitor the 
effects of the test result and assess if the candidate requires any further support [41]. Predictive testing is 
commonly performed for reproductive reasons. Reproductive options for at risk individuals include prenatal 
diagnosis (PND) and termination of pregnancy in the event that the foetus carries the expanded CAG or pre-
implantation genetic diagnosis (PGD) performed during in-vitro fertilisation were only embyros without the 
CAG expansion are transferred. These options are also available to those unaware of their gene status by use 
of an exclusion test, which tests for the mutant HTT allele of the affected grandparent [42].     
Management 
The optimal management of HD involves a multidisciplinary approach involving physicians, nurses, 
physiotherapists, speech and language therapists, dieticians and other health care professionals. The aim is to 
optimize quality of life and pre-empt the changing needs of the patient as the disease progresses. This 
usually involves a combination of pharmacological and non-pharmacological interventions. In many 
instances the evidence base for pharmacological treatments is sparse and decisions are made based on expert 
opinion and clinical experience [43].  
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Motor symptoms 
Chorea is one of the most prominent symptoms in HD and occurs early in the disease. The only drug 
specifically licensed to treat chorea is tetrabenazine [44]. This is a synaptic vesicular amine transport 
inhibitor, which provides a sustained anti-choreic effect at doses in the range 50-75mg per day. Side effects 
include sleep problems, depression, anxiety and restlessness [45].  
  Deutetrabenazine is a modified version of Tetrabenazine that contains deuterium molecules. This 
results in prolonged half-life and less metabolism variability. The FIRST-HD study revealed that compared 
to placebo Deutetrabenzine significantly reduces chorea [46] and while no head-to-head studies have been 
performed comparing Tetrabenazine and Deutetrabenazine, there is the suggestion that Deutetrabenazine 
may result in less side effects, such as depression and somnolence [47].  
 Sulpiride, a neuroleptic, has shown efficacy in treating chorea in a randomised control trial (RCT). In 
clinical practice other neuroleptics including olanzapine, respiridone and quetiapine are also commonly used, 
with sedation and weight gain being the most common side effects [45]. Other motor symptoms such as 
abnormal gait, poor balance and frequent falls are commonly treated with physiotherapy. 
Psychiatric symptoms 
There is limited evidence with regard to the treatment of psychiatric symptoms in HD therefore treatment 
decisions are based on clinical consensus and expert opinion. Depression, anxiety, obsessive compulsive 
disorder and irritability may be treated with non-pharmacological interventions such as cognitive 
behavioural therapy or psychodynamic therapy, however these approaches may be limited in the context of 
cognitive impairment. Pharmacological interventions include selective serotonin uptake inhibitors 
(citalopram, fluoxetine, paroxetine and sertraline) and Mirtazepine and venlafaxine, which have serotonergic 
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and noradrenergic effects. Neuroleptics can be useful in treating aggression and psychosis. A number of 
medications, including methylphenidate, atomoxetine, modafinil, amantadine, bromocriptine and bupropion 
have been used to treat apathy however no RCTs have been performed [48].  
Cognitive symptoms 
Two RCTs have assessed the use of anti-cholinesterase inhibitors for cognition in HD, however participant 
numbers were small and results were conflicting [49]. Another RCT found no effect of citalopram on 
cognitive function [50]. Coping strategies to deal with cognitive deficits can be beneficial. For example 
requesting employers change the type or work or work setting, for example working in a quiet environment 
or changing to work that requires less multi-tasking [51].     
Biomarkers  
Clinical 
The cognitive measures Stroop word reading, symbol digit modalities and circle tracing (direct and indirect) 
are sensitive to longitudinal change in HD over 24 months, however relatively little change is seen in 
premanifest HD over this time course [32]. Quantitative measures of chorea, grip force and speeded tapping 
shows changes in HD over 24 months, with speeded tapping also showing longitudinal change in 
premanifest HD [52]. Longitudinal change in psychiatric measures is more variable and only seen in apathy 
[28].  
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Biofluid Biomarkers  
A number of potential blood biomarkers have emerged. The most promising of these is neurofilament light 
(NFL) protein. Baseline plasma levels of NFL protein show correlation with progression in brain atrophy 
and motor and cognitive measures and over time.  In premanifest HD baseline plasma NFL is associated 
with disease onset over a 3-year period. Plasma NFL is highly correlated with CSF NFL, suggesting 
peripheral blood sampling may be sufficient to accurately detect NFL therefore avoiding the need for more 
invasive CSF collection [53]. Transcription studies using RNA derived from blood reveal abnormal gene 
expression in HD compared to controls, however results have been conflicting [54, 55]. Increases in immune 
proteins in plasma, using a proteomics approach, also show correlation with disease stage [56]. More 
recently it has been possible to detect mHTT from blood-derived monocytes, with levels correlating with 
disease burden and caudate atrophy [57]. Longitudinal studies are yet to reveal whether these approaches 
can detect change over time.  
 Much research has focused on searching for cerebrospinal fluid (CSF) biomarkers [58]. Perhaps the 
most promising of these is the detection of mHTT in CSF. mHTT in the CSF correlates with disease burden 
and is also associated with cognitive and motor performance [59]. Other CSF markers are also linked to 
disease stage, such as tau, neurofilament light and measures of inflammation [60, 61]. HD clarity a large 
multi-site initiative has recently been set up in order to collect large numbers of CSF samples to facilitate 
further CSF biomarker investigation (http://hdclarity.net).    
Imaging 
Structural MRI has been the most extensively studied imaging modality in HD to date. Track-HD evaluated 
changes in both grey and white matter volume at 3 time points one year apart. This study revealed grey 
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matter volume loss in the striatum and loss of white matter volume around the striatum, within the corpus 
callosum and in the posterior white matter tracts in the premanifest stage extending to wide spread loss of 
white mater volume, and to a lesser extent grey matter, in manifest stage [13, 28, 52]. The limited decline in 
cognitive and motor function in the premanifest stage coupled with this grey and white matter volume has 
led to the suggestion that compensatory mechanisms such as neuroplasticity and network reconfiguration 
enable those in the premanifest stage to maintain normal function [52]. 
Diffusion weighted MRI (DWI) can be used to measure the diffusion of water in-vivo and is therefore 
capable of providing information about the microstructure of white matter fibre tracts in the brain [62]. In 
keeping with regional changes in white matter volume, microstructural white matter changes are also seen 
around the striatum, within the corpus callosum and in the posterior white matter tracts [63]. More recently 
studies using diffusion tractography, which can delineate white matter connections, have shown selective 
vulnerability of cortico-striatal white matter connections in premanifest HD, extending to wide spread loss 
of white matter connections in the manifest stage [64].    
 Other imaging modalities such as functional MRI have shown abnormalities both in premanifest and 
manifest disease [65]. Positron emission tomography using a phosphodiesterase 10A tracer has been able to 
detect change in premanifest HD up to 25 years before symptoms onset even before grey and white matter 
changes occur [66].    
Clinical Trials  
Over the past two decades 99 clinical trials have been performed in Huntington’s disease investigating 41 
different compounds. However success rate is low with only 3.5% of trials progressing to the next stage [67]. 
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Currently there are 23 active clinical trials in HD registered with ClinicalTrials.gov (see table 1). In this 
section we will review a number of studies that have completed recently. 
  Pridopidine, a dopamine modulator, has been studied in three large phase 3 trails MermaiHD [68], 
HART [69] and Pride-HD [70], unfortunately none of these studies reached their primary end points. PBT2 
is a metal protein-attenuating compound, which acts to reduce metal induced aggregation of mHTT. In a 
phase 2 trial the Reach2HD study showed this drug was safe and well tolerated and plans are currently 
underway for a phase 3 trial [71].  
 Cysteamine, used in the treatment of cystinosis, increases brain-derived neurotrophic factor, a 
growth factor depleted in the brains of HD patients [6].  The effect of Cysteamine on motor progression in 
HD has been evaluated in 3-year long phase 2/3 trial. This revealed that it was safe and well tolerated 
however effects on motor progression did not reach statistical significance [72]. SIRT1 a member of the 
Sirtuin family and causes reduction of mHTT protein levels [73]. This molecule has been investigated in a 
phase 2 study, but no effect on the UHDRS TMS was seen [74].  
 Phosphodiesterase 10A (PDE10A) is found in the striatum and is reduced in HD patients many years 
before the onset of manifest disease [66]. Inhibition of this enzyme using PDE10A inhibitors has been 
shown to restore basal ganglia circuitry in HD animal models [75]. This compound was recently tested in 
the Pfizer Amaryllis phase 2 trial. Unfortunately this failed to show significant improvement in motor, 
cognitive or behavioural measures [76].   
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Table 1. Active clinical trials in Huntington’s disease (ClinicalTrials.gov accessed 11th July 2017). 
Clinical Trial 
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease 
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest 
Huntington's Disease 
Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD) 
Resveratrol and Huntington Disease 
Exploring Computerised Cognitive Training for People With Huntington's Disease 
Exercise Effects in Huntington's Disease 
Beta Testing of a New Assessment in Huntington's Disease (HD) 
Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study 
A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease 
A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease 
Follow-up Measurement of Brain PDE10A Enzyme Levels in HuntingtonÂ´s Disease Gene Expansion Carriers 
A Clinical Study in Subjects With Huntington's Disease to Assess the Efficacy and Safety of Three Oral Doses of 
Laquinimod 
A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy 
Volunteers and in Patients With Huntington's Disease 
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease 
Effect of Tetrabenazine on Stroop Interference in HD 
Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging 
Assessment of the Psychological, Cognitive and Social Resources of Applicants for Huntington's Disease and 
Presymptomatic Genetic Testing 
Alternatives for Reducing Chorea in HD 
Brain Stimulation in Movement Disorders 
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological 
Pathologies (GREFEX II) 
Electronic-health Application To Measure Outcomes REmotely Clinical Trial 
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases. 
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders 
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DNA and RNA targeting therapies for HD 
Perhaps the most promising approaches with regards to disease modification are the emerging therapies 
aimed at lowering levels of mHTT by targeting either the DNA or RNA of the mHTT gene (see figure 3) [2]. 
RNA targeting can be achieved by using Anti-sense oligonucleotides (ASOs), RNA interference (RNAi) or 
small molecule splicing inhibitors. ASOs are currently being trialed in a first in human phase 1b/2a study 
[77]. They are delivered intra-thecally and catalyse the degradation of HTT mRNA by RNAse H, thereby 
reducing the production of the mHTT protein (see figure 3). In animal models this results in up to 80% 
sustained reduction in HTT mRNA levels [78].  
 In RNAi based approaches RNA molecules bind to mRNA in the cytoplasm, prompting its removal 
by argonaute 2, the RNAse enzyme within the RNA-induced silencing complex (RISE) [79], see figure 3. 
Therapeutic strategies using this approach are currently in the preclinical phase. RNAi delivery is more 
invasive than ASOs requiring intracranial injection into the striatum. However a single treatment may 
provide permanent HTT lowering [2]. Small molecule splicing modifiers have shown promise in animal 
models of small muscular atrophy [80] and screening is currently underway to identify small molecule 
splicing modulators of mHTT [81].   
 Targeting the DNA of mHTT can be achieved using two approaches, zinc finger proteins and the 
CRISPR/Cas9 (clustered inter-spaced short palindromic repeats) system. Zinc fingers are proteins forming a 
structural motif that bind to DNA. Synthetic zinc finger transcription factors targeting CAG have been used 
to reduce levels of mHTT protein in animal models. However as they create non-native proteins they have 
the potential to cause immune reactions thus further work is needed [82].  
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 CRISPR/Cas9 is used by bacterial immune systems in order to cleave foreign DNA. In recent years 
the system has been harnessed as a tool for genome editing with a multitude of applications to human 
disease. This technology has been used in fibroblasts of a HD patient to excise the promoter regions, 
transcription start site and the CAG mutation expansion of the mHTT gene. This resulted in permanent and 
mutant allele specific inactivation of the mHTT gene [83]. Recently the method was successfully tested in 
an HD rodent model [84]. This affirms the feasibility of this approach but much preclinical work is needed 
to bring these rapidly-evolving technologies to the clinic, especially given recent concerns about unexpected 
off-target mutations with CRISPR-Cas9 gene editing [85]. 
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Figure 3. The production of huntingtin protein, and targeted molecular therapies in development to 
reduce it. Yellow marks the pathogenic expanded CAG tract and its polyglutamine product. Therapeutic 
approaches are highlighted with pink boxes. Yellow boxes indicate the most widely accepted toxic species. 
Dotted arrows and grey boxes indicate proposed non-traditional mechanisms for the production of toxic 
species. The chief mechanisms of action of ASOs and RNAi compounds are shown at the bottom. The 
image of huntingtin protein is adapted from reference [86] under a creative commons licence (CC-BY-4.0). 
Reproduced with permissions from [2] 
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Conclusions 
HD is a progressive and devastating disease. Over the last decade there has been a rapid growth in our 
understanding of the natural history of HD and pathogenesis both at the cellular and macroscopic level. To 
date few treatments are available and a number of clinical trials of failed. However the development of 
therapeutic strategies capable of targeting mHTT directly heralds a new era for HD research. Now more than 
even there is a real potential to modify and potential prevent HD.   
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